MX2018006921A - Métodos y composiciones para el tratamiento de úlceras gástricas. - Google Patents

Métodos y composiciones para el tratamiento de úlceras gástricas.

Info

Publication number
MX2018006921A
MX2018006921A MX2018006921A MX2018006921A MX2018006921A MX 2018006921 A MX2018006921 A MX 2018006921A MX 2018006921 A MX2018006921 A MX 2018006921A MX 2018006921 A MX2018006921 A MX 2018006921A MX 2018006921 A MX2018006921 A MX 2018006921A
Authority
MX
Mexico
Prior art keywords
gastric ulcers
compositions
methods
treating gastric
composition
Prior art date
Application number
MX2018006921A
Other languages
English (en)
Inventor
Garg Sanjay
Bova Nicholas
Page Stephen
Original Assignee
Luoda Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905078A external-priority patent/AU2015905078A0/en
Application filed by Luoda Pharma Ltd filed Critical Luoda Pharma Ltd
Publication of MX2018006921A publication Critical patent/MX2018006921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para tratar y/o prevenir úlceras gástricas, dicho método comprende administrar mediante inyección una cantidad terapéuticamente eficaz de una composición que comprende: c) un primer agente seleccionado del grupo que consiste en: un triglicérido de cadena mediana y un triglicérido de cadena larga; y d) un segundo agente que comprende un inhibidor de la bomba de protones o una sal aceptable desde el punto de vista farmacéutico o veterinario, donde la composición se adapta para una liberación sostenida de una cantidad terapéuticamente eficaz del inhibidor de la bomba de protones a un sujeto que lo necesita.
MX2018006921A 2015-12-08 2016-12-08 Métodos y composiciones para el tratamiento de úlceras gástricas. MX2018006921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015905078A AU2015905078A0 (en) 2015-12-08 Methods and Compositions For Treating Gastric Ulcers
PCT/AU2016/051205 WO2017096426A1 (en) 2015-12-08 2016-12-08 Methods and compositions for treating gastric ulcers

Publications (1)

Publication Number Publication Date
MX2018006921A true MX2018006921A (es) 2019-05-16

Family

ID=59012417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006921A MX2018006921A (es) 2015-12-08 2016-12-08 Métodos y composiciones para el tratamiento de úlceras gástricas.

Country Status (17)

Country Link
US (2) US11318123B2 (es)
EP (1) EP3386507B1 (es)
AU (1) AU2016367707B2 (es)
BR (1) BR112018011552A2 (es)
CA (1) CA3007446C (es)
DK (1) DK3386507T3 (es)
ES (1) ES2953929T3 (es)
FI (1) FI3386507T3 (es)
HK (1) HK1254232A1 (es)
HR (1) HRP20231051T1 (es)
HU (1) HUE062857T2 (es)
MX (1) MX2018006921A (es)
PL (1) PL3386507T3 (es)
PT (1) PT3386507T (es)
SI (1) SI3386507T1 (es)
WO (1) WO2017096426A1 (es)
ZA (1) ZA201804478B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146660A1 (en) * 2019-07-16 2021-01-21 Kindred Biosciences, Inc. Equine esomeprazole formulations and methods of use
KR102289089B1 (ko) 2019-12-24 2021-08-11 동아대학교 산학협력단 인후두 역류질환 치료 또는 예방용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004683B1 (ru) 1999-02-23 2004-06-24 Мерк Энд Ко., Инк. Фармацевтическая композиция, содержащая омепразол
WO2004103291A2 (en) 2003-05-16 2004-12-02 Eisai Co., Ltd. Extended release compositions of proton pump inhibitor
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
FR2879930B1 (fr) * 2004-12-23 2007-08-31 Oralance Pharma Sa Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation
CN1813729A (zh) * 2005-02-02 2006-08-09 兰贝克赛实验室有限公司 苯并咪唑化合物的注射制剂
US20090214599A1 (en) 2008-02-21 2009-08-27 Agi Therapeutics Plc Proton pump inhibitor formulations, and methods of preparing and using such formulations
DE102009018133A1 (de) 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
CN103127006B (zh) * 2013-03-08 2014-08-06 苏州特瑞药业有限公司 一种注射用右旋兰索拉唑组合物及其制备方法
CN103222962B (zh) * 2013-05-10 2014-12-24 苏州特瑞药业有限公司 一种注射用埃索美拉唑组合物及其制备方法
CN103239448A (zh) 2013-05-20 2013-08-14 青岛正大海尔制药有限公司 一种注射用埃索美拉唑钠冻干粉组合物及其制备方法
CN103637986B (zh) * 2013-12-12 2016-04-06 挑战（天津）动物药业有限公司 一种奥美拉唑纳米乳液及其制备方法

Also Published As

Publication number Publication date
CA3007446C (en) 2024-01-16
EP3386507A4 (en) 2019-07-17
ZA201804478B (en) 2020-12-23
AU2016367707B2 (en) 2022-01-27
US20180133201A1 (en) 2018-05-17
NZ743099A (en) 2023-12-22
FI3386507T3 (fi) 2023-09-06
AU2016367707A1 (en) 2018-06-21
DK3386507T3 (da) 2023-09-18
EP3386507B1 (en) 2023-06-07
PL3386507T3 (pl) 2023-10-23
HK1254232A1 (zh) 2019-07-12
US11318123B2 (en) 2022-05-03
HRP20231051T1 (hr) 2023-12-22
EP3386507A1 (en) 2018-10-17
BR112018011552A2 (pt) 2018-11-27
WO2017096426A1 (en) 2017-06-15
HUE062857T2 (hu) 2023-12-28
SI3386507T1 (sl) 2023-10-30
CA3007446A1 (en) 2017-06-15
US20220202797A1 (en) 2022-06-30
PT3386507T (pt) 2023-09-11
ES2953929T3 (es) 2023-11-17

Similar Documents

Publication Publication Date Title
NZ736709A (en) Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
TN2017000374A1 (en) TGF-β INHIBITORS
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX339002B (es) El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201592182A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
MX2019002259A (es) Inhibicion de la actividad de la olig2.
MX2018006921A (es) Métodos y composiciones para el tratamiento de úlceras gástricas.
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LUODA PHARMA LIMITED